Investors

Corporate Profile

Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease.

The company’s Orbital Atherectomy Systems treat calcified and fibrotic plaque in arterial vessels throughout the leg and heart in a few minutes of treatment time, and address many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives.

The U.S. FDA granted 510(k) clearance for the use of the Diamondback Orbital ... More >>

Stock Quote

CSII (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$26.06
Change (%) Stock is Up 0.36 (1.40%)
Volume335,105
Data as of 07/02/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Upcoming Events

More >>
There are currently no events scheduled.

Recent News

More >>
06/02/15
Cardiovascular Systems to Present at William Blair & Company's 35th Annual Growth Stock Conference
ST. PAUL, Minn.--(BUSINESS WIRE)--Jun. 2, 2015-- On Thursday, June 11, 2015, Cardiovascular Systems’ (NASDAQ: CSII) President and Chief Executive Officer, David L. Martin, will present at William Blair & Company’s 35th Annual Growth Stock Conference at 9:40 a.m. Eastern Time. You may access the live audio webcast and presentation materials in the Investors section at: www.csi360.com. Presentation materials also will be archived on CSI’... 
05/19/15
New Journal Article Highlights Mechanical Effects of Orbital Atherectomy and Rotational Atherectomy in Treating Heavily Calcified Coronary Lesions
Study Finds Significant Tissue Modification Associated with Orbital Atherectomy Led to Better Stent Apposition and Expansion ST. PAUL, Minn.--(BUSINESS WIRE)--May 19, 2015-- Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII) today announced that a new article e-published in May 2015 in The Journal of Catheterization and Cardiovascular Intervention highlights the mechanical effect of orbital atherectomy (OA) and rotational atherectomy (RA) in treating heavily calcified coronary lesions. The ar... 
05/19/15
Cardiovascular Systems Peripheral and Coronary Data Featured at EuroPCR 2015
Primary Treatment with Diamondback 360® Orbital Atherectomy System Improved Drug Uptake in Cadaveric Peripheral Arteries; ORBIT II Two-year Data Demonstrates Durable Clinical and Economic Results ST. PAUL, Minn. & PARIS--(BUSINESS WIRE)--May 19, 2015-- Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII) today announced that CBSET, a not-for-profit preclinical research institute dedicated to biomedical research, education and advan... 
05/07/15
Cardiovascular Systems Features Two-Year ORBIT II Coronary Data and Long-Term Economic Data in Late-Breaking Presentation at SCAI 2015 Scientific Sessions
Diamondback 360® Coronary Orbital Atherectomy System demonstrated: High two-year freedom from MACE rate, including TLR and TVR Estimated one-year cost savings of up to $4,913 per patient ST. PAUL, Minn. & SAN DIEGO--(BUSINESS WIRE)--May 7, 2015-- Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), featured two-year data from its ORBIT II study of the company’s Diamondback 360® Coronary Orbital Ath... 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.